Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Advanced Cell Technology
Marlborough, Massachusetts, United States
- Ownership
- Private
- Employees
- ~40
- Development stage
- Other
01
Overview
Led the first US FDA-approved human trials using embryonic stem cells (ESCs) to treat retinal diseases; published preliminary safety and efficacy data for dry age-related macular degeneration (AMD) and Stargardt disease (results showed promising safety and early visual improvements at 1–2 year follow-up)
- Therapeutic areas
- Ophthalmology
- Modalities
- Cell therapyStem cell therapyInduced pluripotent stem cell derived therapy
- Industry
- Biotech
02
Partnerships
Licensing deal with BioTime (for ACTCellerate platform)WARF patent license for embryonic stem cell technology
Beyond the preview
Go deeper on Advanced Cell Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Advanced Cell Technology.